38th week of 2013 patent applcation highlights part 57 |
Patent application number | Title | Published |
20130244887 | RAPID GENOTYPING ANALYSIS AND DEVICES THEREOF - The present invention discloses methods, primer, probes, and kits for genotyping various mutations or disease-causing agent. In one embodiment, the present invention is applied to detecting the presence of multidrug-resistant | 2013-09-19 |
20130244888 | COMPOSITIONS AND METHODS FOR NUCLEOTIDE SEQUENCING - The invention provides nucleoside and nucleotide molecules containing cleavable linkers linking a label such as a dye. The invention also provides nucleosides and nucleotide molecules containing a blocking group, either removable or non-removable. The invention additionally provides methods of using the nucleoside and nucleotide molecules containing a cleavable linker and/or a blocking group. | 2013-09-19 |
20130244889 | CONSTRUCT FOR PROMOTING ABSORPTION OF MOLECULES BY A CELL AND METHODS OF USING THE CONSTRUCT - The present invention is directed to a construct for promoting absorption of molecules by a cell and the application thereof in drug and gene delivery. The present invention further describes topographical modulation of endocytosis for drug and gene delivery. | 2013-09-19 |
20130244890 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 2013-09-19 |
20130244891 | TARGETED PROBES OF CELLULAR PHYSIOLOGY - Biosensor comprising an activatable acceptor fluorogen linked via a linker to a donor which transfers energy to the fluorogen on detecting an analyte wherein the fluorogen component reacts and a 100 fold increase in intensity results when the fluorogen interacts non-covalently with an activator e.g. fluorogen activator peptide. | 2013-09-19 |
20130244892 | Risk Factors and Prediction of Adverse Events - Biomarkers, methods, systems, and related teachings are disclosed for diagnosing the risk of an adverse event in a human, where the adverse event can be unstable angina, ischemic stroke, non-ischemic stroke, all-cause stroke, heart failure, all-cause death, and being a candidate for coronary revascularization surgery. | 2013-09-19 |
20130244893 | Methods And Compositions For The Diagnosis And Treatment Of Cancer Resistant To Anaplastic Lymphoma Kinase (ALK) Kinase Inhibitors - Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants. | 2013-09-19 |
20130244894 | NUCLEIC ACID-BASED AUTHENTICATION CODES - This invention relates to a nucleic-acid based product authentication by determining authentication codes comprising target nucleic acids using oligonucleotide probes immobilized on particulate and non-particulate substrates. The presence of the authentication code is determined using detection methods, such as flow cytometric methods, capable of particle discrimination based on the light scattering or fluorescence properties of the particle, or by spatial resolution of oligonucleotides immobilized at specific loci on a substrate. Target-correlated fluorescence signal, originating from a target nucleic acid hybridized to substrate-immobilized oligonucleotide is determined as an indicator of the presence of the authentication code. | 2013-09-19 |
20130244895 | Microwell Arrays for Direct Quantification of Analytes on a Flat Sample - The present invention relates to a bioanalytical device consisting of a microwell array with microwell ( | 2013-09-19 |
20130244896 | IN VITRO METHOD FOR PREDICTING WHETHER A COMPOUND IS GENOTOXIC IN VIVO - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. It provides a method that employs the analysis of expression profiles of microRNAs in cells exposed to a potentially genotoxic compound. It was found that differential expression of a number of microRNAs could reliably predict whether a compound was a genotoxic or a non-genotoxic compound. | 2013-09-19 |
20130244897 | Marker Sequences for Multiple Sclerosis and Use Thereof - The invention relates to novel marker sequences for multiple sclerosis and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for multiple sclerosis diseases the marker sequences. The invention further relates to a diagnostic device containing such marker sequences for multiple sclerosis, especially to a protein biochip and the use thereof. | 2013-09-19 |
20130244898 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications. | 2013-09-19 |
20130244899 | DETECTING INFECTION IN REDUCED PRESSURE WOUND TREATMENT - Provided is a method of detecting infection in a wound caused by an infecting organism at a wound site. Also provided is a system for detecting an infection in a wound at a wound site. Additionally, a porous pad comprising luciferase is provided. | 2013-09-19 |
20130244900 | Gene Expression Profiling in Primary Ovarian Serous Papiliary Tumors and Normal Ovarian Epithelum - Provided herein are methods for detecting ovarian serous papillary carcinoma in an individual. A tumor sample from the individual is examined for gene product expression levels of a group of genes consisting of transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family member I (ARHI), thrombospondin 2, and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) Gene products which are down-regulated compared to those in a control individual indicate the presence of ovarian serous papillary carcinoma | 2013-09-19 |
20130244901 | METHOD AND SYSTEM FOR PROGNOSIS AND TREATMENT OF DISEASES USING PORTFOLIO OF GENES - This disclosure generally relates to a method, a system and a kit for diagnosing and treating various disease conditions using the gene expression value in a given sample obtained from a subject. This disclosure further relates to selecting the right set of genes as a portfolio of genes for a particular disease. Providing a set of appropriate portfolio of gene for studying the gene expression values and using the values as a diagnostic tool is also disclosed. The gene expression value is further used for intervention by pharmaceuticals as a prediction model for the treatment of the disease. An individual may have a personalized health card that may store the gene expression value for that particular individual. A system may store the data for portability and integrated view of the individual's medical data for effective diagnosis and treatment. | 2013-09-19 |
20130244902 | EARLY DETECTION OF PANCREATIC CANCER - This document provides methods and materials involved in the early detection of pancreatic cancer. For example, this document provides methods and materials for assessing nucleic acid obtained from a blood sample of a human for a CpG methylation site profile that, at least in part, indicates that the human has pancreatic cancer. | 2013-09-19 |
20130244903 | MODULATORS OF ALPHA-SYNUCLEIN TOXICITY - Disclosed are compositions and methods for modulating expression of genes that function at the step of ER to Golgi trafficking. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity. | 2013-09-19 |
20130244904 | ESCHERICHIA COLI HAVING A MODIFIED TRANSLATIONAL PROPERTY | 2013-09-19 |
20130244905 | Reporter for RNA Polymerase II Termination - A “tandem” reporter construct is disclosed that is capable of assaying RNA transcription termination. The ratio of expression between an upstream reporter and a downstream reporter as compared to the ratio observed for a control construct provides a measure of the relative rate of successful elongation through the intervening sequence. In one embodiment, two self-cleaving ribozymes separate the reporters from a test sequence between them. | 2013-09-19 |
20130244906 | Microfluidic devices and methods based on massively parallel picoreactors for cell and molecular diagnostics - Microfluidic devices and methods that use massively parallel anchored picoreactors as the basis for cell and molecular diagnostics (e.g., characterizing, isolation, processing, amplification) different particles, chemical compositions or biospecies (e.g., different cells, cells containing different substances, different particles, different biochemical compositions, proteins, enzymes etc.). | 2013-09-19 |
20130244907 | METHOD FOR PREPARING B CELL WHICH PRODUCES HUMAN-TYPE ANTIBODY - Provided is a method for preparing B cells which produce a human-type antibody, comprising substituting an antibody gene of B cells with a human antibody gene, wherein the B cells are non-human vertebrate B cells capable of inducing or halting AID (activation induced cytidine deaminase) expression with the induction of the expression of an exogenous Cre recombinase gene through extracellular stimulation followed by the inversion of the direction of the exogenous AID gene by expressed Cre recombinase. | 2013-09-19 |
20130244908 | CHEMICAL SENSOR ARRAY HAVING MULTIPLE SENSORS PER WELL - Methods and apparatus relating to very large scale FET arrays for analyte measurements. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. In one example, chemFET arrays facilitate DNA sequencing techniques based on monitoring changes in hydrogen ion concentration (pH), changes in other analyte concentration, and/or binding events associated with chemical processes relating to DNA synthesis. | 2013-09-19 |
20130244909 | METHODS AND APPARATUS FOR CLASSIFICATION AND QUANTIFICATION OF MULTIFUNCTIONAL OBJECTS - A method may include accessing data regarding a number of events, where the events were detected by a particle detection apparatus, and identifying a number of groups in the events. Each of the groups includes two or more events, and each event includes one or more of a time stamp, a time duration, a fluorescence intensity, a scatter measurement, a radio frequency signal, a magnetic signal, a neutron scattering measurement, a light scattering measurement, an electron scattering measurement, an audio signal, an acoustic signal, a mechanical signal, an electrical resistance, a thermal property, and a width of fluorescence signal. The method may include identifying a subset of the groups as a number of objects detected by the particle detection apparatus, where each object is identified based at least in part upon one or more quantities, where each quantity is identified by or derived from the respective two or more events. | 2013-09-19 |
20130244910 | Lost Circulation Materials and Methods of Using the Same - A method of servicing a wellbore in contact with a subterranean formation, comprising placing a wellbore servicing fluid comprising a drilling fluid and lost circulation material into a lost circulation zone within the wellbore, wherein the lost circulation material comprises a polyelectrolyte multilayer material and a first counterion. A wellbore servicing fluid comprising a drilling fluid and a lost circulation material comprising a polyelectrolyte multilayer material and a counterion comprising a halide, wherein the LCM has a first state that is hydrophilic. A tunable lost circulation material comprising a base material, a polyelectrolyte multilayer on said base material, wherein the polyelectrolyte multilayer comprises a first electrolyte layer, a second electrolyte layer, and a charged surface, and a counterion, wherein wettability of the lost circulation material is a function of the counterion. | 2013-09-19 |
20130244911 | Foamed Spacer Fluids Containing Cement Kiln Dust and Methods of Use - Disclosed are foamed spacer fluids comprising kiln dust for use in subterranean formations. An embodiment discloses a foamed spacer fluid comprising a partially calcined kiln feed removed from a gas stream comprising SiO2, Al2O3, Fe2O3, CaO, MgO, SO3, Na2O, and K2O; a foaming agent; a gas; and water. | 2013-09-19 |
20130244912 | Delivery of Particulate Material Below Ground - A wellbore fluid is an aqueous carrier liquid with first and second hydrophobic particulate materials suspended therein. The first hydrophobic particles have a higher specific gravity than the second hydrophobic particles and the fluid also comprises a gas to wet the surface of the particles and bind them together as agglomerates. The fluid may be a fracturing fluid or gravel packing fluid and the first particulate material may be proppant or gravel. The lighter second particulate material and the gas both reduce the density of the agglomerates which form so that they settle more slowly from the fluid, or are buoyant and do not settle. This facilitates transport and placement in a hydraulic fracture or gravel pack. One application of this is when fracturing a gas-shale with slickwater. The benefit of reduced settling is better placement of proppant so that a greater amount of the fracture is propped open. | 2013-09-19 |
20130244913 | COMPOSITION AND METHOD OF CONVERTING A FLUID FROM OIL EXTERNAL TO WATER EXTERNAL FOR CLEANING A WELLBORE - An environmentally acceptable water-in-oil microemulsion composition includes at least one emulsifying surfactant, at least one biodegradable hydrocarbon solvent, at least one co-solvent, at least one hydrocarbon co-surfactant, and water. The microemulsion composition may be used in a method for rendering fluids from oil external to water external. The microemulsion composition may be combined with water or a water based fluid to produce a spacer fluid utilized in removing oil and oil-residues from a surface, particularly that of wellbores in the drilling of oil and gas wells. | 2013-09-19 |
20130244914 | Light Weight Proppant With Improved Strength And Methods Of Making Same - Methods are described to make strong, tough, and lightweight whisker-reinforced glass-ceramic composites through a self-toughening structure generated by viscous reaction sintering of a complex mixture of oxides. The invention further relates to strong, tough, and lightweight glass-ceramic composites that can be used as proppants and for other uses. | 2013-09-19 |
20130244915 | Friction Modifier Composition for Lubricants - Combining a metal based friction modifier, such as a molybdenum dialkyldithiocarbamate, and certain esters of hydroxy carboxylic acids, such as short chain alkyl esters of citric or tartaric acid, e.g., tributyl citrate, has a synergistic effect on lowering the friction coefficient of lubricating oils allowing one to reduce the amount of metal based friction modifier needed to adequately formulate a lubricant with low friction characteristics. | 2013-09-19 |
20130244916 | CORROSION INHIBITOR - A food grade corrosion inhibitor for admixture with a food-grade petroleum-based oil is derived from an admixture of food-grade components. The corrosion inhibitor, a food-grade isoalkane, a food-grade ester and imidazoline. The additive is incorporated into a lubricating component such as mineral oil, etc. | 2013-09-19 |
20130244917 | ENGINE LUBRICANT COMPOSITION - Lubricant compositions include: (a) one or more polyalkylene glycol base oils obtained by polymerization or copolymerization of alkylene oxides comprising from 3 to 8 carbon atoms, include at least one butylene oxide and (b) at least one detergent chosen from salicylates or phenates. The present disclosure also relates to: 1) use of a lubricant composition as engine oil, preferably as oil for the engines of petrol or diesel motor vehicles; 2) use of a group of additives for an engine lubricant comprising polyalkylene glycol bases obtained by polymerization or copolymerization of alkylene oxides comprising from 3 to 8 carbon atoms; and 3) use of at least one additive chosen from salicylates, phenates, dithiocarbamates, amine-based or phenol-based antioxidants, preferably from salicylates or phenates, for reducing the Noack volatility of the base oils of polyalkylene glycol type, obtained from alkylene oxides comprising from 3 to 8 carbon atoms. | 2013-09-19 |
20130244918 | Functionalized Copolymers And Lubricating Compositions Thereof - The invention relates to polyester quaternary ammonium salts, including amine, amide, and ester salts, processes for making them, and their use as additives, including their use in fuels, such as diesel fuel and fuel oils. The invention particularly relates to the use of polyester quaternary ammonium salts as detergents in fuels and the methods of making them. | 2013-09-19 |
20130244919 | Compressed Gas Aerosol Composition In Steel Can - An aqueous compressed gas aerosol formulation in combination with a lined steel can, which may also optionally be tin plated, to provide corrosion stability, fragrance stability and color stability. An aerosol formulation of particular advantage for use is an air and/or fabric treatment formulation. The combination provides a compatibility which allows for the ability to use a broader fragrance pallet for the air and/or fabric treatment formulation which is aqueous based in major proportion. The formulation includes, in addition to an aqueous carrier, a fragrance, nonionic surfactant(s) or a blend of nonionic surfactant(s) and cationic surfactant(s), a compressed gas propellant(s), pH adjuster(s), and corrosion inhibitor(s). The formulation has a pH of about 8 to less than 10. The corrosion inhibitor(s) is(are) mild in strength and used in a minor amount. | 2013-09-19 |
20130244920 | WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND METHOD OF MAKING SAME - Disclosed herein are water soluble compositions, such as films, including a mixture of a first water-soluble resin, an enzyme, and an enzyme stabilizer which comprises a functional substrate for the enzyme, methods of making such compositions, and methods of using such compositions, e.g. to make packets containing functional ingredients. The enzymes can include proteases and mixtures of proteases with other enzymes, and the compositions provide good retention of enzyme function following film processing and storage. | 2013-09-19 |
20130244921 | Array of Self-Adhering Articles and Merchandise Display System for Identifying Product Types to Users - An array of self-adhesive cleaning products, the array having a first self-adhesive cleaning product, the product being a gel, and a second self-adhesive cleaning product, the second product being a solid. | 2013-09-19 |
20130244922 | AZEOTROPIC COMPOSITIONS COMPRISING METHYL PERFLUOROPENTENE ETHERS FOR CLEANING APPLICATIONS - The present disclosure provides azeotropic and azeotrope-like compositions comprised of methylperfluoropentene ethers and at least one of methanol, ethanol, 2-propanol, hexane, heptane, trans-1,2-dichloroethylene, ethyl formate, methyl formate, HFE-7100, HFE-7200 and 1-bromopropane or combinations thereof. The present disclosure also provides for methods of use for the azeotropic and azeotrope-like compositions. | 2013-09-19 |
20130244923 | Solid Soap - The object of the present invention is to improve the solidification point and the hardness of a soap of the fatty acid soap series wherein a large amount of myristic acid is blended. The solid soap of the present invention to achieve the above-described object is characterized by comprising a fatty acid soap and 1 to 8 mass % of betaine, and in that the content of myristic acid is 50 mass % or more in the total fatty acid of the fatty acid soap. | 2013-09-19 |
20130244924 | PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM - The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specifically the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage. | 2013-09-19 |
20130244925 | MOLECULES MIMICKING AN AUTOANTIBODY IDIOTYPE AND COMPOSITIONS CONTAINING SAME - Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient. | 2013-09-19 |
20130244926 | MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS - A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient. | 2013-09-19 |
20130244927 | POLYNUCLEOTIDES ENCODING SIGNAL PEPTIDE-CONTAINING MOLECULES - The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP. | 2013-09-19 |
20130244928 | ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES - The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence. | 2013-09-19 |
20130244929 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS - The present invention provides novel lipoglycopeptide compounds which are Type 1 signal peptidase inhibitors (SpsB). Compounds of the present invention are useful for the treatment of various bacterial related infectious diseases, particularly when used as a potentiator of a β-lactam antibiotic such as imipenem and ertapenem. Accordingly, the present invention provides a method for the treatment of bacterial related infections using the compounds described herein, either alone or in combination with a β-lactam antibiotic. | 2013-09-19 |
20130244930 | ANTIFUNGAL AGENTS AND USES THEREOF - The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections. | 2013-09-19 |
20130244931 | Novel GLP-1 Derivatives - Novel polypeptide derivatives having protracted profile of action. | 2013-09-19 |
20130244932 | E-PROSTANOID RECEPTOR, PTGER3, AS A NOVEL ANTI-DIABETIC THERAPEUTIC TARGET - Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition. | 2013-09-19 |
20130244933 | USE OF CONKUNITZIN-S1 FOR THE MODULATION OF GLUCOSE-INDUCED INSULIN SECRETION - The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions. | 2013-09-19 |
20130244934 | VIP FRAGMENTS AND METHODS OF USE - The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder. | 2013-09-19 |
20130244935 | Methods of Treating Necrotizing Enterocolitis Using Heparin Binding Epidermal Growth Factor - Methods of treating, abating and reducing the lisk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include admmistering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC. | 2013-09-19 |
20130244936 | CONSTITUTIVELY ACTIVE PROLACTIN RECEPTOR VARIANTS AS PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS TO PREVENT PROGRESSION OF HORMONE-DEPENDENT CANCERS TOWARDS HORMONE-INDEPENDENCE - The present invention relates to an in vitro method of prognosing outcome of hormone-dependent cancer in a subject comprising detecting a constitutively activating mutation in the prolactin receptor (PRLR) gene in a nucleic acid sample previously obtained from said subject, said constitutively activating mutation being preferably a mutation resulting in the expression of a mutant prolactin receptor wherein the isoleucine residue at position 146 is substituted with leucine or a mutation resulting in the expression of a mutant prolactin receptor wherein the isoleucine residue at position 76 is substituted with valine. | 2013-09-19 |
20130244937 | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION - Therapeutic compositions containing chimeric natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing chimeric natriuretic peptides are further described. | 2013-09-19 |
20130244938 | Relaxin Analogs - Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. | 2013-09-19 |
20130244939 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 2013-09-19 |
20130244940 | DESIGNED REPEAT PROTEINS BINDING TO SERUM ALBUMIN - New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin. | 2013-09-19 |
20130244941 | Use Of C1 Inhibitor For The Prevention Of Ischemia-Reperfusion Injury - The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke. | 2013-09-19 |
20130244942 | IMPLANTABLE MATERIALS FOR BONE REPAIR - The invention features fiber reinforced bone repair putties and fiber reinforced pliable lyophilized implants which are useful for the treatment of bone defects. The putties and lyophilized implants include ceramic particles. The formulations of the invention can exhibit reduced migration of the ceramic particles, and are mechanically strengthened so the materials can be aggressively manipulated by a physician during an implantation procedure without tearing or puncturing. | 2013-09-19 |
20130244943 | HYALURONIC ACID-COLLAGEN MATRICES FOR DERMAL FILLING AND VOLUMIZING APPLICATIONS - Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen. | 2013-09-19 |
20130244944 | Synthetic Ion Channels - Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the ion channels formed from a plurality of molecules of the self-assembling compounds. Further, provided are methods of treating or preventing conditions and diseases that are related to the dysfunction of ion channels, including chloride channels. | 2013-09-19 |
20130244945 | LISSENCEPHALY THERAPEUTIC AGENT - An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): | 2013-09-19 |
20130244946 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES - Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof. | 2013-09-19 |
20130244947 | METHODS AND COMPOSITIONS RELATED TO IMPROVING PROPERTIES OF PHARMACOLOGICAL AGENTS TARGETING NERVOUS SYSTEM - Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system. | 2013-09-19 |
20130244948 | COMPOSITIONS OF CELLS, MEDIA, AND METHODS THEREOF - The disclosure provides a composition that comprises co-culture of small embryonic-like stem cells and mesenchymal stem cells, where cell media is reduced or lacking in exogenously supplied growth factors, as well as compositions of growth media that result from, or are manufactured by, co-culture of at least two types of different cells. Also provided are methods for selecting cell media that meet criteria pertaining to cell migration (gap assays) and to confluence. | 2013-09-19 |
20130244949 | NOVEL ANTICANCER AGENTS COMPRISING PEPTIDES WITH CANCER-SPECIFIC TOXICITY - The present invention relates a prophylactic or therapeutic composition for cancer, and more particularly, to a pro-phylactic or therapeutic composition for cancer comprising a peptide which is represented by an amino acid sequence of the following Formula (I), a method for preventing or treating cancer comprising the step of administering the peptide to a subject, and use of the peptide in the preparation of the prophylactic or therapeutic composition for cancer. (I) APKAMX | 2013-09-19 |
20130244950 | COMBINATION THERAPY FOR CHEMORESISTANT CANCERS - Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 2013-09-19 |
20130244951 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent. | 2013-09-19 |
20130244952 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 2013-09-19 |
20130244953 | DUAL SECURED THERAPEUTIC PEPTIDE DELIVERY SYSTEM - A delivery system is described that includes a polymer network that can incorporate a therapeutic peptide for targeted delivery to a cell, e.g., a cancer cell. The polymer network can secure the therapeutic peptide via two different mechanisms. First, a polymer of the network can interact with the therapeutic peptide via charge/charge interaction to form a complex with the peptide, thereby holding the peptide within the network. Second, the polymer network can be crosslinked, providing another level of securement for holding the therapeutic peptide within the network. The two levels of securement can be reversible, and following delivery of the network to the interior of a targeted cell reversal of the securement mechanisms can release the therapeutic peptide within the cell. | 2013-09-19 |
20130244954 | USE OF REG4 AND PHARMACEUTICAL COMPOSITION THEREOF - The invention is in the field of biotechnology. Specifically it describes the application and pharmaceutical composition of Reg4. The invention describes the applications of the protein as following in (a) or (b) in preparing drugs for treating acute pancreatitis: (a) the protein whose amino acid sequence is shown as SEQ ID NO. 1, or bioactive fragments, or analogs; (b) the proteins whose amino acid sequence have at least 70% homology comparing with amino acid sequence described in (a) and have activity for treating acute pancreatitis. The protein described in this invention treats acute pancreatitis effectively and may provide new therapy for treating acute pancreatitis clinically. | 2013-09-19 |
20130244955 | BINDING PROTEINS FOR HEPCIDIN - The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins. | 2013-09-19 |
20130244956 | CAMPTOTHEAN-PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptidic moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues. | 2013-09-19 |
20130244957 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2013-09-19 |
20130244958 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES - There are provided compounds of the formula | 2013-09-19 |
20130244959 | Composition Containing Styraxlignolide A or the Aglycone Thereof as an Active Ingredient for Preventing or Treating Asthma - The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of | 2013-09-19 |
20130244960 | Treatment for Alzheimer's Disease - Using a Pharmaceutically Suitable Preparation containing one more Cardio Glycosides such as THEVETIN B, THEVETIN A, PERUVOSIDE, THEVOFOLIN, OLEANDRIN, NERIIFOLIN, THEVETOXIN Derived and or Extracted from the Yellow Oleandrin Plant ( | 2013-09-19 |
20130244961 | ABNORMAL INTRAOCULAR PRESSURE TREATMENT - Methods and compositions for reducing intraocular pressure in a patient, particularly a human patient, are described. In particular, compositions are disclosed that contain an anthocyanoside or an extract comprising it, a proanthhocyanidin or an extract comprising it and combinations thereof. The compositions are useful for lowering intraocular pressure. | 2013-09-19 |
20130244962 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES - Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis. | 2013-09-19 |
20130244963 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMIN- O)PYRIMIDINE-5-CARBOXAMIDE - The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia. | 2013-09-19 |
20130244964 | NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS - The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided. | 2013-09-19 |
20130244965 | ASSAYS AND METHODS FOR DETERMINING RISK OF A MACROPHAGE-MEDIATED DISEASE DEVELOPMENT IN A SUBJECT INFECTED WITH HIV - The invention is generally related to assays and methods for determining the risk of an HIV+ individual for developing a macrophage-mediated disease using measurement of soluble CD163 levels in a biological sample. The invention also provides assays and methods for monitoring efficacy of a treatment or a drug for a macrophage-mediated disease, and assays and methods for screening for agents to treat a macrophage-mediated disease in an HIV+ individual by monitoring soluble CD163 levels. | 2013-09-19 |
20130244966 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES - The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate. | 2013-09-19 |
20130244967 | SNS-595 AND METHODS OF USING THE SAME - The present invention relates to SNS-595 and methods of treating cancer using the same. | 2013-09-19 |
20130244968 | Uracyl Spirooxetane Nucleoside Phosphoramidates - This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV). | 2013-09-19 |
20130244969 | Prebiotic Formulations and Methods of Use - The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes. | 2013-09-19 |
20130244970 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2013-09-19 |
20130244971 | STABILIZED OPHTHALMIC GALACTOMANNAN FORMULATIONS - The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride. | 2013-09-19 |
20130244972 | INJECTABLE CHITOSAN MIXTURES FORMING HYDROGELS - A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions. | 2013-09-19 |
20130244973 | COMBINATION OF POLYCHITOSAMINE AND HMG-COA REDUCTASE INHIBITOR FOR HYPERLIPIDEMIA - Combinations of therapeutic compounds for prophylaxis or treatment of hyperlipidemia and hyperlipidemia related disorders, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The combinations are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. The methods of the preferred embodiments comprise administering to a mammal a first amount of polychitosamine and a second amount of an HMG-CoA reductase inhibitor (statin). | 2013-09-19 |
20130244974 | SURGICAL HYDROGEL - A composition suitable for use in wound healing, particularly for reducing post-surgical adhesions, containing cross-linked derivatives of chitosan and dextran polymers. A hydrogel forms when solutions of the polymers are combined. | 2013-09-19 |
20130244975 | CHEMICAL CONJUGATES FOR TARGETED DEGRADATION UNDER REDUCING CONDITIONS - The present invention is related to compositions which can undergo targeted degradation under certain physiological reducing conditions. The compositions may, for example, be hydrogels in which maleimide-functionalized low molecular weight heparin is cross-linked with various thiol-functionalized polyethylene glycol multi-arm star polymers. Both the gelation and degradation of the hydrogels can be modified by careful selection of the thiol. For example, hydrogels prepared from aryl thiol-maleimide adducts can undergo a retro Michael addition-type reaction, leading to degradation of the composition and release of the bioactive molecule. | 2013-09-19 |
20130244976 | FOAM-TYPE EXTERNAL SKIN PREPARATION - The present invention provides a foam-type external skin preparation exhibiting an amount of and a retention of carbon dioxide foam appealing to the eye of the user, as well as good usability, such as in preventing the preparation from sagging from the skin, neither of which can be easily obtained with conventional foam-type external skin preparations. | 2013-09-19 |
20130244977 | COSMETIC BIO-CELLULOSE MASK PACK SHEET AND METHOD FOR MANUFACTURING SAME - The present invention relates to a mask pack sheet using bio-cellulose obtained from fermented ginseng extracts, and more particularly, to a method for manufacturing a cosmetic mask pack sheet, comprising injecting microbial strains into a culture medium containing ginseng extracts so as to ferment the ginseng extracts and prepare a bio-cellulose sheet, and dipping the sheet into a cosmetic liquid. | 2013-09-19 |
20130244978 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses or an ophthalmic composition/solution for contact lenses, which comprises (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid. | 2013-09-19 |
20130244979 | 6-Deoxy-6-Thioether-Amino Acid Cyclodextrin Derivative and Preparation Method Thereof - 6-deoxy-6-thioether-amino acid cyclodextrin derivative is obtained by condensing an amino acid derivative with halogenated cyclodextrin in presence of alkali. The 6-deoxy-6-thioether-amino acid cyclodextrin derivative includes 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative and 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative. Compounds provided are for reversing neuromuscular relaxation in patients and animals induced by muscular relaxants. The compounds are able to rapidly reverse and antagonize muscular relaxation induced by muscular relaxants and can be administrated in preparing a drug having an antagonist effect on muscular relaxation. The compounds have a general formula (I). | 2013-09-19 |
20130244980 | BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. | 2013-09-19 |
20130244981 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME USING OMEGA CHOLINE - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 2013-09-19 |
20130244982 | CONJUGATES OF A PHOSPHOLIPID AND A DRUG FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA | 2013-09-19 |
20130244983 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS - 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na | 2013-09-19 |
20130244984 | Ceramide Production Promoter - Provided are a drug, a cosmetic, etc. for promoting production of ceramide. | 2013-09-19 |
20130244985 | Drug Depots Having Different Release Profiles for Reducing, Preventing or Treating Pain and Inflammation - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain. | 2013-09-19 |
20130244986 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS - Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%. | 2013-09-19 |